• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J.Infect.Dis. Effectiveness of Monovalent A(H1N1)pdm09 and 2010-11 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-11 Season

tetano

Editor, Senior Moderator
J Infect Dis. (2013) doi: 10.1093/infdis/jit020

Effectiveness of Monovalent A(H1N1)pdm09 and 2010-11 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-11 Season

Allen C. Bateman1,
Burney A. Kieke1,
Stephanie A. Irving1,
Jennifer K. Meece1,
David K. Shay2 and
Edward A. Belongia1

+ Author Affiliations

1Marshfield Clinic Research Foundation, Marshfield, WI, USA
2Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA

Corresponding author: Edward A. Belongia, MD, Telephone: (715) 389-3783, Fax: (715) 389-3880, E-mail: belongia.edward@marshfieldclinic.org

Abstract

Background. Influenza A(H1N1)pdm09 viruses did not exhibit antigenic drift in the 2010-11 season, providing an opportunity to investigate duration of protection after vaccination. We estimated the independent effects of 2010-11 trivalent seasonal vaccine (TIV) and 2009 pandemic vaccine for preventing medically attended influenza A in the 2010-11 season.

Methods. Individuals were tested for influenza by reverse transcription polymerase chain reaction (RT-PCR) after a clinical encounter for acute respiratory illness. Case-control analyses compared participants with RT-PCR-confirmed influenza A and test negative controls. Vaccine effectiveness (VE) was estimated separately for monovalent pandemic vaccine and 2010-11 TIV; VE was calculated as 100?(1 ? odds ratio) with adjustment for potential confounders.

Results. The effectiveness of 2010-11 TIV against influenza A was 63% [95% confidence interval (CI), 37% to 78%]. Effectiveness of TIV against A(H1N1)pdm09 virus infection was 77% (95% CI, 44% to 90%). Monovalent vaccine administered between October 2009 and April 2010 was not protective in the 2010-11 season. VE of monovalent vaccine was −1% (95% CI, −146% to 59%) against A(H1N1)pdm09 in 2010-11.

Conclusions. Monovalent vaccine provided no sustained protection against A(H1N1)pdm09 during the 2010-11 season. This waning effectiveness supports the need for annual revaccination, even in the absence of antigenic drift.


http://jid.oxfordjournals.org/content/early/2013/01/20/infdis.jit020.abstract
 
Back
Top Bottom